Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Active, not recruiting · NCT03326336 · Registry updated 2026-03-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, cone-rod dystrophy, eye disorder, hereditary disease, inherited retinal dystrophy, retinal degeneration, retinal disorder, retinitis pigmentosa | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-02 | NCT03326336 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GenSight Biologics | 2 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Hospitalier National d'Ophtalmologie (CHNP) des Quinze-Vingts | Paris | France | 1 |
| Moorfields Eye Hospital NHS Foundation Trust, 162 City Road | London | United Kingdom | 1 |
| UPMC Eye Center | Pittsburgh | United States | 6 |